RecruitingNot ApplicableNCT04199026

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Sarcomas


Sponsor

M.D. Anderson Cancer Center

Enrollment

20 participants

Start Date

Feb 25, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This early phase I trial studies the side effects of implanting and removing a microdevice in patients with sarcomas that have spread to other places in the body (metastatic) or have come back (recurrent). Microdevices are rice-sized devices that are implanted into tumor tissue and are loaded with 10 different drugs that are delivered at very small doses, or "microdoses," which may only affect a very small, local area inside the tumor. The purpose of this study is to determine which drugs delivered in the microdevice affect tumor tissue in patients with sarcomas.


Eligibility

Min Age: 10 Years

Inclusion Criteria4

  • Patients with a biopsy-confirmed recurrent or metastatic sarcoma for which surgery is indicated as a standard of care.
  • years of age or older
  • Documented, signed, dated informed consent to participate in the microdevice study
  • Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2

Exclusion Criteria4

  • Subjects who do not wish to undergo surgical resection, or those who are high-risk or not candidates for surgical resection
  • Age \< 10 years old
  • Women of childbearing potential without a negative pregnancy test; or women who are lactating
  • Allergies or prior adverse drug reactions to any of the drugs loaded within the microdevice.

Interventions

DRUGDoxorubicin

Given via microdevice

DRUGDoxorubicin Hydrochloride

Given via microdevice

DEVICEDrug Delivery Microdevice

Undergo percutaneous implantation of drug delivery microdevice

DRUGEverolimus

Given via microdevice

BIOLOGICALGanitumab

Given via microdevice

DRUGIfosfamide

Given via microdevice

DRUGIrinotecan

Given via microdevice

DRUGPazopanib

Given via microdevice

DRUGPolyethylene Glycol

Given via microdevice

DRUGTemozolomide

Given via microdevice

DRUGTemsirolimus

Given via microdevice

PROCEDURETherapeutic Conventional Surgery

Undergo standard of care surgery

DRUGVincristine

Given via microdevice


Locations(1)

M D Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04199026


Related Trials